Northstrive Biosciences, a subsidiary of PMGC (ELAB) Holdings announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists. The Company filed the following four patents today: EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals; EL-32 in Obesity as Monotherapy and Combination with GLP-1: Updated patent filings for Pharmaceutical Composition for Treatment of Muscle Loss Due to Obesity Treatments and Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments utilizing GLP-1 receptor agonists; EL-32 in Animals: Animal Feed Additive to Encourage Muscle Growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Northstrive Biosciences Gains FDA Support for EL-22
- PMGC announces preliminary responses from U.S. FDA on EL-22
- PMGC Holdings Announces Acquisition of IT Packaging Firm
- PMGC signs letter of intent to acquire U.S.-based custom IT packaging company
- PMGC’s Northstrive Biosciences signs partnership with Yuva Biosciences